Drug Trial Radar · NCT05954312
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
290
Planned (sponsor's estimate)
Start
Jul 28, 2023
Primary completion
Aug 31, 2030
Study completion Feb 28, 2031
Sponsor
- Lead sponsor
- Vividion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.
Conditions
- Advanced Solid Tumors
Interventions
VVD-130037Drug
Oral tablets
DocetaxelDrug
IV infusion
PaclitaxelDrug
IV infusion
PembrolizumabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 (Dose Escalation): Incidence and Severity of Dose-limiting Toxicities (DLTs) During DLT Observation PeriodTime frame: Part 1: Single Agent and Docetaxel/Pembrolizumab Combination Therapy: From Day 1 to Day 21 of Cycle 1 [cycle length=21 days] and Part 1: Paclitaxel Combination Therapy: From Day 1 to Day 28 of Cycle 1 [cycle length=28 days]
- Part 2 (Dose Expansion): Number of Participants With AEs, Serious Adverse Events (SAEs), and Clinical Laboratory AbnormalitiesTime frame: Up to approximately 4 years
Locations
26 sites in 3 countries. Site status is shown where the registry gives one.
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Florida Cancer Specialists
Sarasota, Florida · Recruiting
Moffitt Cancer Center
Tampa, Florida · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
MDACC
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Virginia
Fairfax, Virginia · Recruiting
National Cancer Center
Goyang, South Korea · Recruiting
The Catholic University of Korea, St. Vincent's Hospital
Goyang, South Korea · Recruiting
Gachon University Gil Medical Center
Incheon, South Korea · Recruiting
Seoul National University; Bundang Hospital
Seongnam, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital; Yonsei University Health System
Seoul, South Korea · Recruiting
The Catholic University of Korea, St. Vincent's Hospital
Suwon, South Korea · Recruiting
Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
START Barcelona Hospital HM Nou Delfos
Barcelona, Spain · Recruiting
Hospital Universitario 12 de Octubre
Madrid, Spain · Recruiting
Hospital Universitario Ramon y Cajal
Madrid, Spain · Recruiting
NEXT Madrid
Madrid, Spain · Recruiting
START Madrid CIOCC
Madrid, Spain · Recruiting
Start Madrid-FJD, Hospital Fundacion Jimenez Diaz
Madrid, Spain · Recruiting
Clinica Universitaria de Navarra
Pamplona, Spain · Recruiting
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.